Read more: http://www.bloglution.com/2013/08/how-to-enable-rss-auto-discovery-in.html#ixzz2ik0NTKwC

Friday, August 16, 2013

Top Rated Report: Chronic Myeloid Leukemia Drugs Market - Global Survey Report, Size, Share, Growth, Trends And Forecast 2013-2019

Chronic Myeloid Leukemia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019


Chronic Myeloid Leukemia (CML) is a type of blood cancer caused by uncontrolled growth of the cells in bone marrow. CML is a type of myeloproliferative disease which is characterized by the chromosomal translocation. Patients suffering from CML show increased susceptibility to infections, thrombocytopenia, anemia and may also have enlarged spleen which causes pain on the left side.

To Read The Complete Report with  TOC:-

Incidence rate of CML is high in men and is the second most common type of cancer occurring in male adults. Women who are above 50 years in age are expected to suffer from this chronic disease. Treatment for CML depends on the phase of the disease that can be chronic, accelerated or the blast phase and the treatments for CML include chemotherapy, stem cell transplants and biologic therapies. Drugs available in the market are tyrosine Kinase inhibitor. 

About 90% of the CML cases occur in the middle age and progresses with the aging. Therefore, CML drugs market is poised to grow with the rise in aging population and increasing incidences of CML. Drugs such as Gleevec (Imatinib Mesylate), Bosulif (Bosutinib), Sprycel (Dasatinib), Iclusig (Ponatinib Hydrochloride) and others are commercially available for the treatment of CML. These drugs have improved the survival rate of the patient by 92.5%. Gleevec was the first CML drug introduced in 2001, since then there has been a revolutionary change in the quality life of patient as compared to the former chemotherapy drugs.

One of the major risk factor associated with occurrence of CML is the exposure to ionizing radiations. For instance cases of CML were mainly indicated in the regions where people were exposed to atomic bombings (Hiroshima and Nagasaki). Recently in 2012, Ponatinib received FDA approval for the treatment of CML. Further, players in the market are adopting various growth strategies such as mergers and acquisitions, new product launches, innovative product pipeline to remain competitive. Some of the market players in this industry are Novartis Pharmaceuticals, Bristol-Myers Squibb, Ariad Pharmaceuticals, Inc, Pfizer and others. 


To Buy a Copy Of This Report:-    

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 

·         North America 
·         Asia Pacific 
·         Europe
·         Rest of the World  



Contact:-
M/s  Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email:        sales@marketresearchreports.biz 
Blog:          http://marketsbuzz.wordpress.com/ 

1 comment:

  1. Irrespective of receiving daily oral or future injectable depot therapies, these require health care visits for medication and monitoring of safety and response. If patients are treated early enough, before a lot of immune system damage has occurred, life expectancy is close to normal, as long as they remain on successful treatment. However, when patients stop therapy, virus rebounds to high levels in most patients, sometimes associated with severe illness because i have gone through this and even an increased risk of death. The aim of “cure”is ongoing but i still do believe my government made millions of ARV drugs instead of finding a cure. for ongoing therapy and monitoring. ARV alone cannot cure HIV as among the cells that are infected are very long-living CD4 memory cells and possibly other cells that act as long-term reservoirs. HIV can hide in these cells without being detected by the body’s immune system. Therefore even when ART completely blocks subsequent rounds of infection of cells, reservoirs that have been infected before therapy initiation persist and from these reservoirs HIV rebounds if therapy is stopped. “Cure” could either mean an eradication cure, which means to completely rid the body of reservoir virus or a functional HIV cure, where HIV may remain in reservoir cells but rebound to high levels is prevented after therapy interruption.Dr Itua Herbal Medicine makes me believes there is a hope for people suffering from,Parkinson's disease,Schizophrenia,Lung Cancer,Breast Cancer,Lupus,Lymne Disease,psoriasis,Colo-Rectal Cancer,Blood Cancer,Prostate Cancer,siva,Epilepsy Dupuytren's disease,Desmoplastic small-round-cell tumor Diabetes ,Coeliac disease,Brain Tumor,Fibromyalgia,Alzheimer's disease,Adrenocortical carcinoma Infectious mononucleosis. .Asthma,Allergic diseases.Hiv_ Aids,Herpe ,Copd,Glaucoma., Cataracts,Macular degeneration,Cardiovascular disease,Chronic Myelo ,Lung disease,Enlarged prostate,Osteoporosis,Dementia.(measles, tetanus, whooping cough, tuberculosis, polio and diphtheria),Chronic Diarrhea,Hpv,All Cancer Types,Diabetes,Hepatitis, I read about him online how he cure Tasha and Tara so i contacted him on drituaherbalcenter@gmail.com / . even talked on whatsapps +2348149277967 believe me it was easy i drank his herbal medicine for two weeks and i was cured just like that isn't Dr Itua a wonder man? Yes he is! I thank him so much so i will advise if you are suffering from one of those diseases Pls do contact him he's a nice man.

    ReplyDelete